JP2022503792A5 - - Google Patents
Info
- Publication number
- JP2022503792A5 JP2022503792A5 JP2021516496A JP2021516496A JP2022503792A5 JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5 JP 2021516496 A JP2021516496 A JP 2021516496A JP 2021516496 A JP2021516496 A JP 2021516496A JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5
- Authority
- JP
- Japan
- Prior art keywords
- caution
- optionally substituted
- alkyl
- independently
- membered heterocycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736974P | 2018-09-26 | 2018-09-26 | |
| US62/736,974 | 2018-09-26 | ||
| PCT/US2019/053015 WO2020069027A1 (en) | 2018-09-26 | 2019-09-25 | Treatment of hematological malignancies with inhibitors of menin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022503792A JP2022503792A (ja) | 2022-01-12 |
| JP2022503792A5 true JP2022503792A5 (https=) | 2022-10-04 |
Family
ID=69949505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516496A Pending JP2022503792A (ja) | 2018-09-26 | 2019-09-25 | メニン阻害剤を用いた血液悪性腫瘍の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230095934A1 (https=) |
| EP (1) | EP3856173A4 (https=) |
| JP (1) | JP2022503792A (https=) |
| CN (1) | CN113164443A (https=) |
| WO (1) | WO2020069027A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| TW202525813A (zh) * | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
| BR112023015210A2 (pt) | 2021-01-29 | 2023-11-07 | Cedilla Therapeutics Inc | Inibidores de cdk2 e métodos de uso dos mesmos |
| US20240417405A1 (en) | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
| CA3215379A1 (en) * | 2021-05-08 | 2022-11-17 | Olivier Alexis Georges Querolle | Substituted spiro derivatives |
| PE20240588A1 (es) * | 2021-05-11 | 2024-03-21 | Janssen Pharmaceutica Nv | Terapias de combinacion |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| JP2024521902A (ja) | 2021-06-03 | 2024-06-04 | ヤンセン ファーマシューティカ エヌ．ベー． | スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン |
| WO2022257047A1 (en) * | 2021-06-09 | 2022-12-15 | Acerand Therapeutics (Hong Kong) Limited | Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof |
| WO2022262796A1 (en) | 2021-06-17 | 2022-12-22 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CA3225439A1 (en) | 2021-06-26 | 2022-12-29 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| CN118234497A (zh) * | 2021-12-15 | 2024-06-21 | 丹娜-法伯癌症研究所 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
| US20250152591A1 (en) * | 2022-02-04 | 2025-05-15 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AR130379A1 (es) * | 2022-09-02 | 2024-12-04 | Hutchmed Ltd | Compuestos de triazina y usos de los mismos |
| CN120456907A (zh) * | 2022-11-02 | 2025-08-08 | 库拉肿瘤学公司 | 急性白血病的治疗方法 |
| WO2024112819A1 (en) * | 2022-11-22 | 2024-05-30 | Dana-Farber Cancer Institute, Inc. | Men1 mutations and uses thereof |
| CN120529900A (zh) * | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN118994033B (zh) * | 2023-05-17 | 2025-09-16 | 成都先导药物开发股份有限公司 | 一种sdnx-5613的合成方法及其中间体化合物 |
| IL325861A (en) * | 2023-07-17 | 2026-03-01 | Kura Oncology Inc | Crystalline forms of menin inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3140423A1 (en) * | 2014-05-07 | 2017-03-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New biomarker for aml |
| USRE49687E1 (en) * | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| AU2016324920B2 (en) * | 2015-09-14 | 2022-03-03 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
| US10869868B2 (en) * | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PL3429591T3 (pl) * | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| PH12018501955B1 (en) * | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) * | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| EA201991078A1 (ru) * | 2016-11-02 | 2019-11-29 | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| WO2018106820A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EP3558991A2 (en) * | 2016-12-23 | 2019-10-30 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
-
2019
- 2019-09-25 JP JP2021516496A patent/JP2022503792A/ja active Pending
- 2019-09-25 EP EP19867072.1A patent/EP3856173A4/en active Pending
- 2019-09-25 CN CN201980078019.9A patent/CN113164443A/zh active Pending
- 2019-09-25 WO PCT/US2019/053015 patent/WO2020069027A1/en not_active Ceased
- 2019-09-26 US US17/278,527 patent/US20230095934A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022503792A5 (https=) | ||
| JP6952097B2 (ja) | ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター | |
| CN104000806B (zh) | 端粒酶活化化合物及其使用方法 | |
| JP2020514388A5 (https=) | ||
| CN116354960A (zh) | Shp2磷酸酶抑制剂 | |
| US11654149B2 (en) | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | |
| JP2019521988A (ja) | 癌を処置するためのｅｚｈ２阻害剤 | |
| JP2018524298A (ja) | リンパ腫を処置するためのｅｚｈ２阻害剤 | |
| ZA200105399B (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases. | |
| EP1423080A2 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
| JP7747351B2 (ja) | ベンゼン環化合物及びその使用 | |
| CA3246041A1 (en) | Tetracyclic compound and its use | |
| EP0512817A1 (en) | Pyridazinedione derivatives, their preparation and pharmaceutical applications | |
| WO2018200571A1 (en) | Substituted 2,3-dihydro-1h-indene analogs and methods using same | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| JP2023524230A5 (https=) | ||
| RU2025136491A (ru) | Производное 3,4-дигидрофталазин-1(2h)-она, способ его изготовления и его применение | |
| JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
| EA047636B1 (ru) | Соединения и способы их применения | |
| WO2023002323A1 (en) | Synthesis of substituted tricyclic amides and analogues thereof | |
| AU2022399786A1 (en) | Compounds | |
| WO2024089272A1 (en) | New inhibitors of phosphatidylinositol 3-kinase | |
| HK40105830A (zh) | 用於治疗与核糖体障碍相关的贫血的组合物和方法 | |
| IE42878B1 (en) | 4-amino-3-benzylideneamino-1,2,4-triazoles-methods for their preparation and their use | |
| JPWO1998042329A1 (ja) | 血管新生異常に起因する疾患の予防および／または治療剤 |